Sign in

You're signed outSign in or to get full access.

Wilbert Tauzin

Director at Avalon GloboCare
Board

About Wilbert J. Tauzin II

Wilbert J. Tauzin II (age 82) has served on ALBT’s Board since November 1, 2017. He is a former U.S. Representative (12.5 terms for Louisiana’s 3rd District), chaired the House Energy & Commerce Committee (Jan 2001–Feb 2004), led PhRMA as President & CEO (Dec 2004–Jun 2010), and served as Special Legislative Counsel at Alston & Bird (Dec 2010–Mar 1, 2014). He holds a BA from Nicholls State University and a JD from Louisiana State University .

Past Roles

OrganizationRoleTenureCommittees/Impact
U.S. House of RepresentativesMember (LA-3rd)12.5 termsDeputy Majority Whip; Senior Member, Resources Committee; Chair, Energy & Commerce (Jan 2001–Feb 2004)
PhRMAPresident & CEODec 2004–Jun 2010Led major industry lobbying efforts
Alston & Bird LLPSpecial Legislative CounselDec 2010–Mar 1, 2014Legislative advisory

External Roles

OrganizationRoleTenure/StatusNotes
LHC Group (public until 2021)Lead Independent Director; Lead Independent EmeritusLead Independent Director 2005–2021; Emeritus currentHome health care provider; governance leadership
Entergy (Fortune 500)DirectorPrior service (dates not disclosed)Large regulated utility; board experience
Louisiana State Savings & Loan AssociationFounder/Chair of first boardPriorFinancial services experience

Board Governance

  • Independence: ALBT’s Board determined four directors are independent (Sanders, Felix, Stilley, Troy); Tauzin is not listed among independent directors under Nasdaq and SEC rules .
  • Committees: Audit (Stilley, Sanders, Troy; Chair Stilley), Compensation (Felix, Sanders, Troy; Chair Felix), Nominating (Sanders, Stilley, Troy; Chair Sanders). Tauzin is not a member of any standing committee .
  • Attendance: Board met 5 times in 2024; each director attended at least 75% of Board and relevant committee meetings .
  • Code of Conduct / Anti-Hedging: Directors are subject to ALBT’s Code and insider trading policy prohibiting hedging/monetization (e.g., collars, forwards) .
  • Clawback: Equity awards under the Amended and Restated 2020 Plan are subject to ALBT’s clawback policy adopted Nov 16, 2023 .

Fixed Compensation

Component20232024
Cash fees ($)$0 $25,000
Option awards ($)$38,052 $4,697 (1,333 options vested)
Total ($)$38,052 $29,697

Notes:

  • 2024 footnote: 1,333 options vested, valued at $4,697 .
  • Peer comparison (context): Other non-employee directors in 2024 received $60,000–$100,000 cash plus option values of ~$2,697; Tauzin’s cash retainer notably lower at $25,000 .

Performance Compensation

Metric20232024
Director performance metrics tied to equity/cashNot disclosed (director comp comprised cash and vested options; no performance targets cited) Not disclosed (director comp comprised cash and vested options; no performance targets cited)
Plan-level performance award availabilityPlan permits performance-based awards generally; no director-specific metrics disclosedPlan permits performance-based awards generally; no director-specific metrics disclosed
Clawback applicabilityClawback policy applies to awards under Amended & Restated 2020 Plan Clawback policy applies to awards under Amended & Restated 2020 Plan

Other Directorships & Interlocks

CompanyRelationship to ALBTPotential Interlock/Conflict Considerations
LHC GroupNo disclosed transactions with ALBTGovernance experience; no interlock noted with ALBT customers/suppliers
EntergyNo disclosed transactions with ALBTPrior utility board; no interlock noted with ALBT

Expertise & Qualifications

  • Healthcare policy and regulatory leadership (Chair, House Energy & Commerce; Deputy Majority Whip) .
  • Industry advocacy (PhRMA CEO) .
  • Legal and legislative advisory experience (Alston & Bird) .
  • Education: BA (Nicholls State University), JD (Louisiana State University) .

Equity Ownership

CategoryShares/Options% of Outstanding
Common shares owned directly1,037 <1.0%
Options exercisable within 60 days4,266 <1.0%
Total beneficial ownership5,303 <1.0%

Additional notes:

  • Section 16(a) compliance: ALBT reports all directors timely filed for FY2024 .
  • No disclosure of pledging or hedging of ALBT stock; hedging prohibited by policy .

Governance Assessment

  • Independence and conflicts: Tauzin is not classified as an independent director under Nasdaq rules; additionally, ALBT discloses consulting services by Tauzin and his son totaling $63,644 (2024) and $86,528 (2023), with accrued unpaid amounts ($15,000 at Dec 31, 2024/2023; $2,733 at Jun 30, 2025). This is a related-party transaction and a governance red flag for potential conflicts and board independence .
  • Committee participation: He holds no committee seats (Audit, Compensation, Nominating), limiting direct oversight roles; this may weaken board effectiveness signals tied to him personally .
  • Attendance: Meets minimum attendance (≥75%); Board held 5 meetings in 2024, suggesting baseline engagement .
  • Pay structure: 2024 cash retainer of $25,000 is markedly below peers ($60,000–$100,000), with small option value ($4,697). The low cash fee may indicate reduced engagement/role scope vs peers, but also lowers cash outlay; no performance-based director pay is disclosed .
  • Alignment mechanisms: Equity ownership is small (<1%); options are exercisable but no ownership guidelines disclosed for directors. Anti-hedging and clawback policies are positive structural safeguards .

RED FLAGS

  • Related-party consulting by Tauzin and family members creates actual and perceived conflict risk (repeat transactions in 2023–2024 with continuing accruals) .
  • Not independent per Board determination and lacks committee roles central to oversight (Audit/Comp/Nominating), reducing direct governance impact .